Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity
Tumor plasticity refers to tumor cell's inherent property of transforming one type of cell to different types of cells. Tumor plasticity is the main cause of tumor relapse, metastasis and drug resistance. Cancer stem cell (CSC) model embodies the trait of tumor plasticity. During carcinoma prog...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00887/full |
| _version_ | 1818502607432318976 |
|---|---|
| author | Xiao-Guang Yang Lan-Cao Zhu Yan-Jun Wang Yan-Yu Li Dun Wang |
| author_facet | Xiao-Guang Yang Lan-Cao Zhu Yan-Jun Wang Yan-Yu Li Dun Wang |
| author_sort | Xiao-Guang Yang |
| collection | DOAJ |
| description | Tumor plasticity refers to tumor cell's inherent property of transforming one type of cell to different types of cells. Tumor plasticity is the main cause of tumor relapse, metastasis and drug resistance. Cancer stem cell (CSC) model embodies the trait of tumor plasticity. During carcinoma progression, epithelial-mesenchymal transition (EMT) plays crucial role in the formation of CSCs and vasculogenic mimicry (VM) based on epithelial-mesenchymal plasticity. And the unique tumor microenvironment (TME) not only provides suitable niche for CSCs but promotes the building of CSCs and VM that nourishes tumor tissue together with neoplasm metabolism by affecting tumor plasticity. Therapeutic strategies targeting tumor plasticity are promising ways to treat malignant tumor. In this article, we discuss the recent developments of potential drug targets related to CSCs, EMT, TME, VM, and metabolic pathways and summarize drugs that target these areas in clinical trials. |
| first_indexed | 2024-12-10T21:12:31Z |
| format | Article |
| id | doaj.art-70640109e8bf4c508f931c72f454a7e8 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-10T21:12:31Z |
| publishDate | 2019-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-70640109e8bf4c508f931c72f454a7e82022-12-22T01:33:24ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-09-01910.3389/fonc.2019.00887486874Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor PlasticityXiao-Guang YangLan-Cao ZhuYan-Jun WangYan-Yu LiDun WangTumor plasticity refers to tumor cell's inherent property of transforming one type of cell to different types of cells. Tumor plasticity is the main cause of tumor relapse, metastasis and drug resistance. Cancer stem cell (CSC) model embodies the trait of tumor plasticity. During carcinoma progression, epithelial-mesenchymal transition (EMT) plays crucial role in the formation of CSCs and vasculogenic mimicry (VM) based on epithelial-mesenchymal plasticity. And the unique tumor microenvironment (TME) not only provides suitable niche for CSCs but promotes the building of CSCs and VM that nourishes tumor tissue together with neoplasm metabolism by affecting tumor plasticity. Therapeutic strategies targeting tumor plasticity are promising ways to treat malignant tumor. In this article, we discuss the recent developments of potential drug targets related to CSCs, EMT, TME, VM, and metabolic pathways and summarize drugs that target these areas in clinical trials.https://www.frontiersin.org/article/10.3389/fonc.2019.00887/fulltumor plasticitycancer stem cellsvasculogenic mimicryextracellular matrixtumor microenvironmenttargeting |
| spellingShingle | Xiao-Guang Yang Lan-Cao Zhu Yan-Jun Wang Yan-Yu Li Dun Wang Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity Frontiers in Oncology tumor plasticity cancer stem cells vasculogenic mimicry extracellular matrix tumor microenvironment targeting |
| title | Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity |
| title_full | Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity |
| title_fullStr | Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity |
| title_full_unstemmed | Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity |
| title_short | Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity |
| title_sort | current advance of therapeutic agents in clinical trials potentially targeting tumor plasticity |
| topic | tumor plasticity cancer stem cells vasculogenic mimicry extracellular matrix tumor microenvironment targeting |
| url | https://www.frontiersin.org/article/10.3389/fonc.2019.00887/full |
| work_keys_str_mv | AT xiaoguangyang currentadvanceoftherapeuticagentsinclinicaltrialspotentiallytargetingtumorplasticity AT lancaozhu currentadvanceoftherapeuticagentsinclinicaltrialspotentiallytargetingtumorplasticity AT yanjunwang currentadvanceoftherapeuticagentsinclinicaltrialspotentiallytargetingtumorplasticity AT yanyuli currentadvanceoftherapeuticagentsinclinicaltrialspotentiallytargetingtumorplasticity AT dunwang currentadvanceoftherapeuticagentsinclinicaltrialspotentiallytargetingtumorplasticity |